Monument Tx has a well-balanced pipeline that includes two independent programmes with different and substantial central nervous system indications each with a significant unmet medical need. Proprietary biomarkers developed by the Monument Tx team allows precise selection of the patients most likely to benefit from treatment. The therapeutic products under development are novel formulations utilising generic actives with a known safety profile or will expand the label of approved generics.

The development plan for each programme permits rapid progress with early proof-of-concept data leading to Phase II clinical development.

Monument Pipeline

Contact us to learn more about our pipelines

Contact Us